Century Therapeutics, Inc. (IPSC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Century Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies for cancer and autoimmune diseases. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company. As of June 30, 2024, the company had 84.55 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $0.77 million | $1.63 million | $1.82 million |
| Net Loss | $(31.21) million | $(59.27) million | $(64.56) million |
| Net Loss Per Share (Basic/Diluted) | $(0.38) | $(0.82) | $(1.10) |
| Operating Expenses | $35.53 million | $67.69 million | $68.98 million |
| Cash & Cash Equivalents | $41.46 million | $41.46 million | $47.32 million (Dec 31, 2023) |
| Short-term & Long-term Investments | $228.17 million | $228.17 million | $214.51 million (Dec 31, 2023) |
| Total Liquidity (Cash + Investments) | $269.63 million | $269.63 million | $261.83 million (Dec 31, 2023) |
| Long-term Debt | $0 | $0 | $0 |
Note: The company has no long-term debt outstanding as the Hercules Capital loan was repaid in May 2023.
Material Changes vs. Prior Period
- Acquisition of Clade Therapeutics: On April 11, 2024, the company acquired Clade Therapeutics for a total consideration of approximately $39.7 million (cash, stock, and contingent consideration). This added $33.3 million in in-process research and development (IPR&D) and $5.1 million in goodwill to the balance sheet.
- Capital Raises: During the six months ended June 30, 2024, the company raised approximately $74.4 million in net proceeds through an At-The-Market (ATM) offering ($17.8 million) and a Private Investment in Public Equity (PIPE) transaction ($56.6 million).
- Revenue Recognition: Collaboration revenue decreased slightly year-over-year for the six-month period ($1.63M vs $1.82M) due to the timing of expense recognition under the Bristol-Myers Squibb agreement.
- Operating Expenses: Total operating expenses decreased by $1.3 million year-over-year for the six-month period, primarily driven by a $4.2 million impairment charge in Q2 2023 that did not recur in 2024, partially offset by increased R&D costs related to the Clade acquisition and clinical trial progression.
- Interest Income: Interest income increased to $6.82 million for the six months ended June 30, 2024, compared to $5.68 million in the prior year, due to higher interest rates on investment balances.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments ($269.6 million) are sufficient to fund operations into 2026.
- Clinical Progress:
- CNTY-101 (Cancer): The ELiPSE-1 Phase 1 trial for CD19+ B-cell malignancies is ongoing. Dose escalation for schedules A and B is complete; the company is enrolling in the dose confirmation portion.
- CNTY-101 (Autoimmune): The CALiPSO-1 Phase 1 trial for Systemic Lupus Erythematosus (SLE) has initiated. The protocol was amended to include a Lupus Nephritis cohort. Initial data is expected by year-end 2024.
- Strategic Focus: The company is expanding clinical development for CNTY-101 into additional autoimmune indications and leveraging the Clade acquisition to enhance its Allo-Evasion technology and pipeline.
- Risks:
- Dependence on the success of lead product candidate CNTY-101.
- Need for additional capital to fund future operations and commercialization.
- Reliance on third-party collaborators (Bristol-Myers Squibb, FUJIFILM Cellular Dynamics) for technology, manufacturing, and commercialization.
- Regulatory risks associated with novel cell therapies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $269.6 million liquidity position against the projected burn rate into 2026, considering the increased R&D spend from the Clade acquisition.
- Clade Integration: Monitor the integration of Clade's three preclinical programs and the valuation of the $9.3 million contingent consideration liability.
- CNTY-101 Data: Await the release of initial clinical data from the CALiPSO-1 (SLE) trial expected by year-end 2024 and continued updates from the ELiPSE-1 (Cancer) trial.
- Collaboration Revenue: Track the recognition of revenue from the Bristol-Myers Squibb agreement, which is the primary revenue source, and the status of the $109.8 million in long-term deferred revenue.
- Capital Markets: Assess the company's ability to raise additional capital if needed, given the dilution from recent ATM and PIPE offerings.